475 related articles for article (PubMed ID: 21675498)
1. Calcipotriene 0.005% and betamethasone dipropionate 0.064% combination topical suspension (Taclonex Scalp).
Scheinfeld NS
Skinmed; 2011; 9(3):179-80. PubMed ID: 21675498
[No Abstract] [Full Text] [Related]
2. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
Jemec GB; Ganslandt C; Ortonne JP; Poulin Y; Burden AD; de Unamuno P; Berne B; Figueiredo A; Austad J
J Am Acad Dermatol; 2008 Sep; 59(3):455-63. PubMed ID: 18694678
[TBL] [Abstract][Full Text] [Related]
3. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis.
Kin KC; Hill D; Feldman SR
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):789-97. PubMed ID: 27089906
[TBL] [Abstract][Full Text] [Related]
4. Taclonex (calcipotriene 0.005% and betamethasone dipropionate 0.064%) ointment.
Abramovits W; Perlmutter A; Gupta AK
Skinmed; 2006; 5(3):136-8. PubMed ID: 16687982
[No Abstract] [Full Text] [Related]
5. A betamethasone-calcipotriene combination for psoriasis.
Med Lett Drugs Ther; 2006 Jul; 48(1238):55-6. PubMed ID: 16841023
[TBL] [Abstract][Full Text] [Related]
6. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
McCormack PL
Am J Clin Dermatol; 2011 Dec; 12(6):421-4. PubMed ID: 21967117
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland.
Affleck AG; Bottomley JM; Auland M; Jackson P; Ryttov J
Curr Med Res Opin; 2011 Jan; 27(1):269-84. PubMed ID: 21142836
[TBL] [Abstract][Full Text] [Related]
9. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.
Menter A; Gold LS; Bukhalo M; Grekin S; Kempers S; Boyce BM; Ganslandt C; Villumsen J; Lebwohl M
J Drugs Dermatol; 2013 Jan; 12(1):92-8. PubMed ID: 23377334
[TBL] [Abstract][Full Text] [Related]
10. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
[TBL] [Abstract][Full Text] [Related]
11. Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial.
Silver S; Tuppal R; Gupta AK; Clonier F; Olesen M; Leeder R; Taraska V
J Drugs Dermatol; 2013 Aug; 12(8):882-7. PubMed ID: 23986161
[TBL] [Abstract][Full Text] [Related]
12. Real-life treatment profile of calcipotriene and betamethasone dipropionate topical suspension in patients with psoriasis vulgaris.
Bagel J; Levi E; Tyring S; Knuckles ML
J Drugs Dermatol; 2014 Nov; 13(11):1374-9. PubMed ID: 25607705
[TBL] [Abstract][Full Text] [Related]
13. Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis.
Girolomoni G; Vena GA; Ayala F; Cannavò SP; De Pità O; Chimenti S; Peserico A
G Ital Dermatol Venereol; 2012 Dec; 147(6):609-24. PubMed ID: 23149707
[TBL] [Abstract][Full Text] [Related]
14. The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis - an introduction.
Freeman K
Curr Med Res Opin; 2011 Jan; 27(1):197-203. PubMed ID: 21142834
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.
Eichenfield LF; Ganslandt C; Kurvits M; Schlessinger J
Pediatr Dermatol; 2015; 32(1):28-35. PubMed ID: 25412565
[TBL] [Abstract][Full Text] [Related]
16. Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris.
Fleming C; Ganslandt C; Leese GP
J Drugs Dermatol; 2010 Aug; 9(8):969-74. PubMed ID: 20684147
[TBL] [Abstract][Full Text] [Related]
17. Using a single product (calcipotriene/betamethasone topical suspension) vs multiple products to manage body and scalp psoriasis: comparisons in resource utilization and costs.
Feldman SR; Levi E; Pathak P; Kakatkar S; Balkrishnan R
J Med Econ; 2013 Dec; 16(12):1405-13. PubMed ID: 24063352
[TBL] [Abstract][Full Text] [Related]
18. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial.
Tyring S; Mendoza N; Appell M; Bibby A; Foster R; Hamilton T; Lee M
Int J Dermatol; 2010 Nov; 49(11):1328-33. PubMed ID: 20964660
[TBL] [Abstract][Full Text] [Related]
19. Treatments for scalp psoriasis with emphasis on calcipotriol plus betamethasone dipropionate gel (Xamiol).
Guenther LC
Skin Therapy Lett; 2009 May; 14(4):1-4. PubMed ID: 19585059
[TBL] [Abstract][Full Text] [Related]
20. [New treatment of scalp psoriasis--discrepancy between headlines and content].
Mobacken H
Lakartidningen; 2009 Apr 22-28; 106(17):1200. PubMed ID: 19530436
[No Abstract] [Full Text] [Related]
[Next] [New Search]
